1. Metabolic Enzyme/Protease
  2. Phosphatase
  3. AQX-435


Cat. No.: HY-136268
Handling Instructions

AQX-435 is a potent SHIP1 activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth.

For research use only. We do not sell to patients.

AQX-435 Chemical Structure

AQX-435 Chemical Structure

CAS No. : 1619983-52-6

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review


AQX-435 is a potent SHIP1 activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth[1].

In Vitro

AQX-435 reduces CLL cell viability in a dose-dependent manner[1].
AQX-435 (5-30 µM; 24 hours)-induced apoptosis was mediated via caspases since AQX435 induced PARP cleavage[1].
AQX-435 effectively inhibits PI(3,4,5)P3-mediated signaling downstream of the BCR in CLL and DLBCL cells[1]. AQX-435 and ibrutinib combine effectively to enhanced inhibition of BCR signaling. AQX-435 induced TMD8 cell apoptosis in vitro with an IC50 of ~2 µM. AQX-435 reduces anti-IgM-induced AKT phosphorylation and induces apoptosis in DLBCL cells[1].

Cell Viability Assay[1]

Cell Line: Chronic lymphocytic leukemia (CLL) cells
Concentration: 5-30 µM
Incubation Time: 24 hours
Result: Reduced CLL cell viability in a dose-dependent manner.
In Vivo

AQX-435 (10 mg/kg; i.p.; 5 days) significantly reduced the volume of TMD8 tumors[1].
AQX-435 (50 mg/kg; ip) inhibits DLBCL PDX tumors growth[1].
AQX-435 reduced AKT phosphorylation and growth of DLBCL in vivo and cooperated with ibrutinib for tumor growth inhibition[1].

Animal Model: NOD.Cg-Prkdc scidIl2rgtm1Wjl/SzJ mice (NSG mice) (TMD8 tumors)[1]
Dosage: 10 mg/kg
Administration: I.p.; in 7-day cycles each comprising 5 days of AQX-435 followed by 2 days with no drug
Result: Reduced the volume of TMD8 tumors.
Molecular Weight







O=C(C1=CC=CN=C1)N[[email protected]@H]2C[[email protected]@]3([H])C(C)(C)CCC[[email protected]]3(C)[[email protected]@H](C(C4=CC(O)=CC(O)=C4)=O)[[email protected]@H]2C


Room temperature in continental US; may vary elsewhere.


Please store the product under the recommended conditions in the Certificate of Analysis.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


AQX-435AQX435AQX 435PhosphataseApoptosisB-cellchroniclymphocyticleukemiacaspasesPARPAKTphosphorylationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name



Applicant Name *


Email address *

Phone number *


Organization name *

Department *


Requested quantity *

Country or Region *



Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.:
MCE Japan Authorized Agent: